",/-Hydroxybutyrate (GHB) is a naturally occurring compound present in micromolar concentration in both brain (1,2) and in peripheral tissues (3). This endogenous compound is remarkable in that pharmacological doses of 200-500 mg/kg produce marked behavioral and electroencephalographic changes (4), a profound decrease in cerebral glucose utilization (5), an increase in striatal dopamine levels (6) and a decrease in body temperature (7). High doses of GHB have also been reported to protect neurons (8) and intestinal epithelium (9) against cell death resulting from experimental ischemia. Behavioral changes are not seen with doses of less than 30 mg/ kg, but low doses stimulate the release of prolactin, growth hormone and cortisol (10,11), and doses of 5-10 mg/kg result in an increase in body temperature (12). These actions, and the discovery of high affinity binding sites for GHB in the central nervous system (13), suggest that GHB may have a biological function. Both the origin of endogenous GHB and its catabolism are, therefore, of considerable interest. This review will cover the early work on the degradative pathway for GHB and the discovery of a dual pathway for the initial step in the oxidative catabolism of GHB. The factors which regulate the activity of the
enzymes in these pathways, and as a consequence, regulate tissue levels of GHB are also discussed.
Walkenstein et al. (14) established that GHB is largely disposed of, in vivo by oxidation to CO2 and water. These investigators could not find the 14C label from GHB in succinate in urine, but they did find that the label could be trapped in hippuric acid in the urine of animals treated with sodium benzoate as might be expected if GHB were undergoing 13-oxidation. They therefore proposed that GHB was metabolized by 13-oxidation (14) . M6hler et al. (15) and Doherty et al. (16) , however, assayed citric acid cycle intermediates in the tissues of animals given [14C] GHB and demonstrated that the carbon skeleton of GHB indeed does enter the citric acid cycle as succinate rather than as acetyl-CoA as would be expected if GHB were being oxidized through the 13-oxidation pathway.
They proposed the following pathway: 1) GHB ~ succinic semialdehyde 2) Succinic semialdehyde ---> succinate 3) Succinate .... Co2 + H20 The discovery of a metabolic disease in which GHB and succinic semialdehyde (SSA) are markedly elevated (17) in both blood and urine due to a block in SSA dehydrogenase (18) added evidence to support a degradative pathway in which GHB is oxidized to SSA, which in turn is oxidized to succinate.
At the time the pathway shown above was proposed, it was known that the enzymes of the citric acid cycle catalyzed the reactions in step (3) and that SSA dehydrogenase (the enzyme missing in patients with GHB aciduria (18) ) catalyzed the reaction in step (2) .
Step (1) is always depicted as an essential part of this scheme. However, at the time this pathway was proposed, an enzyme or enzymes which could catalyze this step had not been identified.
Isolation of a Cytosolic GHB Dehydrogenase. Two unusual oxidoreductases, one cytosolic (19) and the other mitochondrial (20) , that catalyze the oxidation of GHB to SSA have now been isolated. The cytosolic enzyme, which will be referred to as GHB-dehydrogenase in this review, was first purified to homogeneity from hamster liver (19) and was found to be an NADP+-dependent oxidoreductase. A study of the substrate specificity of purified GHB-dehydrogenase revealed that o-glucuronate and L-gulonate, the product of D-glucuronate reduction, were also good substrates (19) . The physical characteristics, as well as the substrate and inhibitor specificity of this enzyme, indicate that the ability to catalyze the oxidation of GHB probably represents a previously unreported activity for the NADP+-dependent oxidoreductase (EC 1.1.1.19) commonly known as Dglucuronte reductase (21) . This enzyme may also be identical to the group of enzymes categorized in a 1985 review by Cromlish et al. (22) as "ALR-I", the high K m aldehyde reductase or L-hexonate dehydrogenase.
Although the oxidation of GHB catalyzed by this GHB-dehydrogenase proceeds at an easily measurable rate when assayed in vitro under optimal conditions, the very 10w activity found in the in vitro system under conditions simulating those in the c,fiosol raises the question of how, or indeed whether, this enzyme catalyzes the oxidation of GHB in vivo. An answer to this question may have been found when it was discovered that GlIB dehydrogenase could catalyze the reduction of D-glucuronate coupled to the oxidation of GHB (23) as shown below:
GHB + NADP + ~ SSA + NADPH + H + D-glucuronate + NADPH + H + ~ L-gulonte + NADP + The overall or "coupled" reaction is:
GHB + D-glucuronate ~-SSA + L-gulonate When the kinetic constants for the coupled system were determined, it was found that they were more favorable to oxidation of GHB under conditions present in cytosol of most tissues than were those for the uncoupled system.
The time course of the coupled reaction ( Figure 1 ) in which both products, SSA and NADPH, were measured, shows that in the presence of an adequate concentration of D-glucuronate, only a very small net amount of NADPH is formed even though SSA formation is (23) . The reaction mixture contains 10 mM GHB, 1.0 mM D-glucuronate, 0.1 mM NADP § 80 mM phosphate buffer, pH 7.6, enzyme and sufficient water to bring the volume to 1.0 ml. SSA and NADPH were determined as previously described (19) .
proceeding rapidly. This is in contrast to the control reaction mixture without glucuronate in which NADPH and SSA are formed in stoichiometric amounts (19) . These results indicate that NADPH is being used for the reduction of D-glucuronate at the same rate at which it is being produced by the oxidation of GHB. This would account for the low steady state level of NADPH seen in Figure 1 . The effect of increasing concentrations of D-glucuronate on the rate of oxidation of GHB to SSA in the presence of limiting amounts of NADP + and inhibitory amounts of NADPH is shown in Figure 2 . Un, der these conditions, 2 mM o-glucuronate increased SSA formation 8-fold. Other important changes in the kinetic constants for this reaction occur in the presence of D-glucuronate (Table I). The Km (4.5 X 10-4M) for the coupled reaction is five-fold lower and the Vm~-, (1.52 ixmol/min/mg prorein) is 1.8 times higher than in the uncoupled reaction. The effects of coupling and changes in pH on the rate of degradation of GHB are, however, more accurately described by changes in k (the first order rate constant for the reaction) than they are by changes in Vm~x, The concentration Of GHB in the tissues is much lower than Km and under these conditions the quantity Vmax/K m provides a good approximation of k (24) . In the coupled reaction, the rate constant for GHB degradation, VmJ I~, is increased 9-fold as compared to the 1.8-fold increase in Vm~ at saturating concentrations of GHB and NADP § ( strate concentrations found in vivo than in the standard in vitro assay where Vm= conditions are used. In the coupled reaction the Km for NADP § is decreased from 2 x 10 .5 to 1.4 x 10-6M and the inhibition produced by NADPH (Ki = 7 x 10-6M) has been eliminated ( Figure 3 ). GHB can now be oxidized in the presence of an otherwise extremely inhibitory concentration of NADPH. All of the kinetic constants for the coupled reaction are closer to the tissue concentration range shown in Table I ( 25) than are those for the uncoupled reaction. The rate of GHB oxidation is pH-dependent. Earlier work had shown that the pH optimum for the cytosolic oxido-reductase under Vma~ conditions was 9.0 (19), but at a more physiological pH (7.0-7.2) the enzyme was only half as active. The pH optimum was dependent on GHB concentration in both the coupled and uncoupled reactions and in both cases was above 8.0 when saturating concentrations of substrate were used (26) . As the concentration of GHB decreases toward levels found in vivo the pH optimum for the coupled reaction shifts toward pH 7.0 (26) . A plot of VmJKm against pH (Figure 4) shows that, at substrate concentrations near those found in vivo, the pH optimum approaches the intracellular pH, i.e. 7.5 for the uncoupled reaction and 7.13 or lower for the coupled reaction (26) . Vayer et at. (27) subsequently reported a pH optimum of 8.0 under different conditions from those described above. In their system the oxidation of GHB catalyzed by the cytosolic oxidoreductase was coupled to both the reduction of Dglucuronate and the transamination of SSA to form GABA.
GHB dehydrogenase is inhibited by a number of products of intermediary metabolism (Table II) which includes the ketone bodies, et-ketoglutarate and branched a-ketoacids derived from amino acid degradation as well as degradation products of phenylalanine (26) . As has been found with certain aldehyde reductases (28, 29) , anticonwlsants such as barbiturates, diphenylhydantoin and valproate are good inhibitors of GHB dehydrogenase (30) . In addition, GHB dehydrogenase is inhibited by salicylates (30) .
GI-I'B dehydrogenase like lysozyme, ribonuclease and a number of other proteins (26) , may contain disulfide bridges which are essential for its activity. It is inhibited by compounds such as 13-mercaptoethanol and dithiothreitol (DTT), which can reduce disulfide bonds (26) . DTT has the most pronounced effect; addition of 2.5 mM DTT produces an 85% inhibition of the activity Assays for the coupled reaction and the uncoupled reaction were carried out as described (26) . "It should be noted that the ~ has only been reported for the DLmixture. were taken from reference (26) . The data in Figure 4B are from reference (19) . VmJKm = the first order rate constant, k, when IS] < < Kin.
of the purified enzyme and 2.0 mM DTT inhibits 84% of the activity found in rat liver cytosol. The inhibition produced by DTT can be partially reversed by the addition of H202 or completely reversed by oxidized glutathione. Preincubation of GHB dehydrogenase with 2.5 mM DTT before it is added to the reaction mixture (and thereby diluted 50 fold) does not inhibit the enzyme. Under these conditions, the sulfhydryl groups are probably reoxidized by molecular oxygen. Little or no stimulatory effect is seen when compounds such as H202, oxidized glutathione and cystamine, all of which can oxidize sulfhydryl groups, are added to enzyme that has not been previously inhibited by sulfhydryl reducing agents.
When the activity of GHB dehydrogenase is being measured, the inclusion of reducing compounds such as [3-mercaptoethanol or DTT in the assay mixture as has been reported by some laboratories (27) could lead to incorrect results.
Identification of a Mitochondrial Transhydrogenase
Which Catalyzes the o~-Ketoglutarate-Dependent Oxidation of GHB. The discovery of GHB dehydrogenase made it possible to complete a sequence of reactions leading from GHB to CO2 and H20. Development of a polyclonal antibody to the GHB dehydrogenase then made it possible to determine whether or not there were additional enzymes in the cytosol or in other subcellular fractions that could catalyze the initial, and probably rate-limiting, step in the oxidation of GHB to CO2 (31) . The antibody, which inhibited = 95% of the ability of the cytosolic fraction to oxidize GHB to SSA, failed to inhibit approximately 60% of this activity in kidney homogenate ( Figure 5 ). These results suggested that there was at least one additional enzyme which catalyzed the conversion of GHB to SSA. The mitochondrial fraction, which had previously been shown to lack GHB dehydrogenase activity (19) , could oxidize [14C]GHB to 14CQ and could catalyze the pyridine nucleotide-independent oxidation of GHB to SSA (31) . The mitochondrial enzyme was subsequently isolated and shown to be a hydroxyacid-oxoacid transhydrogenase which catalyzed the following reaction (20) : GHB + cx-ketoglutarate---> SSA + oL-hydroxyglutarate. : was used as a measure of activity in the experiments in which homogenate was used. When cytosol was used, the conversion of GHB to SSA was measured spectrophotometrically. The cytosol and homogenate used in this experiment were derived from the same amount of kidney. Antibody was added to the reaction mixture in the amounts indicated.
The oxidation of GHB by the mitochondrial enzyme was found to be completely dependent on the presence of ~x-ketoglutarate. The reaction was reversible. The mitochondrial enzyme also catalyzed the conversion: ~x-hydroxyglutarate + SSA--~ a-ketoglutarate + GHB with the two products being formed in stoichiometric amounts. The substrate specificity is shown in Table III and the kinetic constants for the principal substrates in Table IV ( 20) . The assumption that this enzyme is a transhydrogenase was confirmed when it was shown by gas chromatographic-mass spectroscopy that a deuterium on the hydroxyl-bearing carbon of one of the optical isomers of DL-',/-deutero-',/-hydroxybutyrate was transferred to the ketone-bearing carbon of c~-ketoglutarate. This hydroxyacid-oxoacid transhydrogenase which has been found in the soluble fraction of mitochondria from liver, kidney and brain has been partially purified (20) .
Comparison of the Cytosolic and Mitochondrial Enzymes which Oxidize GHB to SSA. With the discovery of the mitochondrial transhydrogenase it became apparent that there was a dual pathway for the initial step in the oxidative pathway for GHB. Both cytosolic GHB dehydrogenase and the mitochondrial enzyme are oxidoreductases, but of remarkably different types. The cytosolic enzyme is an NADP+-dependent dehydrogenase, whereas the mitochondrial enzyme is a pyridine nucleotide-independent, e~-ketoglutarate-dependent transhydrogenase. These two enzymes, despite some striking differences, have one property in common: the activity of each of these enzymes is regulated by coupling the oxidation of GHB, the hydroxyacid, to the simultaneous reduction of an oxoacid. Though GHB dehydrogenase can function in the uncoupled state, conditions in the cytosol of most tissues (Table I) would not be favorable to the uncoupled reaction. The mitochondrial enzyme, on the other hand, has an absolute requirement for an oxoacid, which suggests that the metabolism of GHB by the mitochondrial enzyme would depend on the steady state levels of citric acid cycle intermediates and of (xketoglutarate in particular. The relative activities (Vm~, and v) of these two enzymes in brain and kidney are shown in Table V . The activities of the two enzymes were measured under Vm~,, conditions; the rate of GHB oxidation (v) at average tissue GHB concentrations could then be calculated (Table V) . How well these values correspond to measurements of GHB catabolism in vivo can be determined by examination of the half-life of GHB in brain. Doherty et al. (16) and M6hler et al. (15) have both reported a half-life (tl/:) for labeled GHB in brain of 5 min. If one assumes that the rate of disposal of GHB follows first order kinetics, then from the fol- lowing expression k, the first order rate constant, can be calculated. k = 2.3 log 2 / tl/2 At a brain concentration of 2.3 nmol/g the rate of disposal of GHB, calculated from the tlj2 would be 0.32 nmol/min/g. The combined rate of catabolism in brain by the two enzymes was found to be 0.18 nmol/min/g brain (Table V) . Since the rate of disposal of GHB calculated from the tissue half-life must include both the rate of catabolism of GHB and the rate of loss from brain by transport to the plasma, the rates calculated from the half-life in brain and from the combined activity of the two catabolic enzymes (Table V) are in reasonable agreement.
Effects of Modulators of GHB Dehydrogenase In
Vivo. One approach used to determine the magnitude of the contribution of GHB dehydrogenase to the metabolism of GHB in vivo was to give rats compounds which inhibit the activity of the enzyme in vitro (30) . If GHB dehydrogenase plays a significant role in the metabolism of GHB in a tissue, inhibition of the enzyme in vivo would be expected to result in increased tissue concen. trations of GHB. Two metabolic intermediates, phenylacetate and c~-ketoisocaproate, and two drugs, valproate and salicylate, all potent inhibitors of GHB dehydrogenase with Ki values in the range of 10 -4 to 10 -5 M, were administered to rats. The effects of c~-ketoisocaproate and phenylacetate (Table VI) and valproate and salicylate (table VII) on tissue contents of GHB varied depending on both the tissue and the compound. All of these compounds increased the concentration of GHB in one or more of the tissues assayed, in some cases by 200%. These results are in agreement with those of Snead (32) who found elevated levels of GHB in brain following administration of sodium valproate. Although each of these compounds also inhibits SSA dehydrogenase (30) , which catalyzes the second step in the degradative pathway, it is very unlikely that the degree to which this enzyme would be inhibited is sufficient to elevate the concentration of SSA enough to cause the increase in tissue levels of GHB. The values for the Ki for valproate, for GABA transaminase (29) and for SSA dehydrogenase (29, 30) are approximately 10 -2 to 10-3M. These Ki values are several orders of magnitude higher than the N for GHB dehydrogenase (30) . From these data it was calculated (30) that sodium valproate at a tissue Vm~,, data is from reference (41) , I~ data are from references (23) and (20), tissue concentrations reference (3). :~K~ for GHB when the oxidation of GHB is coupled to the reduction of D-glucuronate (23 Phenylacetate (1.0 M) was given intravenously as an initial bolus of 1.5 ml followed by a constant infusion of --2.0 ml/h for 2 h. a:Ketoisocaproate (0.5 M) was given intravenously as an initial bolus of 0.6 ml followed by a constant infusion of = 2.0 ml/h for 2 h. At the end of the infusion the animals were killed and the tissues were removed and assayed for GHB as described (30) . All values are means • SEM, numbers of animals are in parentheses. ap < 0.01 bp < 0.05 Sodium valproate (100 mg/kg i.p.) was given 2 hr prior to decapitation; Sodium salicylate (500 mg&g i.p.) was given 1 hr prior to decapitation. Tissues were removed and assayed as described (30) . All values are means • SEM, numbers of animals are in parentheses. "p < 0.01 bp < 0.05 level of 0.3 mM, a reasonable tissue concentration expected in therapeutic use, would produce an 85% inhibition of GHB dehydrogenase but only a 5% inhibition of SSA dehydrogenase and a negligible inhibition of GABA transaminase. It has been reported that sodium valproate inhibits the conversion of SSA to GHB by an aldehyde reductase (EC 1.1.1.2) (29) which may be similar to, or identical to, GHB dehydrogenase (EC 1.1.1.19). However, inhibition of GHB synthesis would not explain the increased tissue levels of GHB seen following administration of sodium valproate. The kinetic constants which have been determined for GHB dehydrogenase in vitro suggest that, in the uncoupled state, the enzyme would be more likely to synthesize GHB from SSA than to oxidize it. Indeed the identical enzyme, D-glucuronic reductase, is classified as an aldehyde reductase. It is only in the coupled state that the kinetic constants become favorable to the oxidation of GHB catalyzed by this oxidoreductase under in vivo conditions. In kidney, D-glucuronate is likely to be one of the aldehydes coupled to the oxidation of GHB.
In this organ myo-inositol oxygenase, the enzyme that synthesizes D-glucuronate, has been found to exist as a complex with o-glucuronate reductase (GHB dehydrogenase) and is believed to transfer the newly formed Dglucuronate directly to the oxidoreductase (33) . Further proof that this oxidoreductase is probably identical to GHB dehydrogenase came from the finding that 95% of the 9-glucuronate reductase activity in kidney cytosol and 80% of that activity in brain cytosol could be titrated with the polyclonal antibody to GHB dehydrogenase (31). What is not known is the extent to which the reaction is coupled in vivo and whether or not there are aldehydes other than D-glucuronate that can serve this role.
To test the extent to which the enzyme is coupled in vivo, the effect of i.v. administration of o-glucuronate on the half-life of [14C]GHB in plasma has been examined (30) . The half-life of 14C-labeled GHB in plasma reflects the overall rate of GHB metabolism by the body tissues since urinary loss of the compound is insignificant (34) . The effect of the administration of L-gulonate, the product of D-glucuronate oxidation and a competitive inhibitor, was also examined (30) . The results shown in Figure 6 demonstrate that the half-life of GHB in plasma is shortened by D-glucuronate. The ability of D-glucuronate to decrease the half-life of GHB in plasma indicates that GHB dehydrogenase is not completely coupled in vivo. The half-life of GHB in plasma is lengthened by L-gulonate as would be expected from a competitive inhibitor of the enzyme. The effect of inhibitors of GHB dehydrogenase on tissue content and plasma half-life of GHB and the effect of D-glucuronate on the plasma halflife both suggest that this enzyme may play an important role in the metabolism of GHB in vivo.
NADPH is another endogenous inhibitor of GHB dehydrogenase (Ki = 7 • 10 -6 M) in the uncoupled state. The results of the experiment in which D-glucuronate was administered to rats have shown that the reaction was not completely coupled since the rate of metabolism could be stimulated by D-glucuronate. In the absence of maximal coupling, changes in the ratio of NADPH/NADP § such as would occur with low ambient oxygen concentration might be expected to decrease the activity of GHB dehydrogenase and thereby increase the tissue concentration of GHB. The data in Table VIII show that in rats exposed to 5.6% oxygen for 2 hours the concentration of endogenous GHB is increased in brain from 3.0 to 10.7 nmol/gm of brain (a 3.6-fold increase) and in kidney from 24.6 to 57.0 nmol/gm of kidney (a 2.3-fold increase). This change in the redox 40  60  80  100  120  140  160  180  20O TIME {rain) Fig. 6 . The effect of D-glucuronate and g-gulonate on the half-life (TI/2) of GHB in plasma (30) . Animals that received o-glucuronate received a bolus containing 240 mg followed by an infusion of 320 mg/h for 3 h. Animals receiving L-gulonate received a bolus of 333 mg and an infusion of 556 mg/h for 3 h. The tl/2 for the disappearance of [14C]GHB from plasma was determined as described. *p < 0.05; 9 *p < 0.025. Animals were exposed to either room air or 5.6% oxygen for 2 hr before decapitation. Tissues were removed and assayed as have been described (3) . Results are expressed as means _ SEM. *p = 0.0005 state would also favor the synthesis of GHB by SSA reductase, an NADPH-dependent enzyme (35) .
Fate of the Carbon Skeleton of GHB. Although GHB is a short chain acid and might be expected to undergo B-oxidation (14) , the markedly elevated plasma SSA and GHB concentrations in patients with GHB aciduria (17, 18) provide evidence that B-oxidation cannot be the major route of degradation. Inasmuch as the major portion of GHB proceeds through oxidation to SSA, the fate of the SSA formed either by GHB dehydrogenase or the mitochondrial transhydrogenase must be considered. Several investigators have isolated metabolic products formed in vivo after administration of labeled GHB (15, 16, 27, (36) (37) (38) (39) . The label is distributed in citric acid cycle intermediates and in aspartate, glutamate and GABA. Several reports indicate that the specific activity of GABA is higher than that found in glutamate. Therefore, it has been suggested (37, 39) that the GHB skeleton may be converted to GABA by GABA transaminase instead of traversing a more circuitous route leading through the citric acid cycle and glutamate decarboxylase. The work cited above shows that [14C]GHB can label the GABA pool and, in fact, conversion of GHB to GABA has been demonstrated in an in vitro system containing purified GHB dehydrogenase and GABA transaminase (27) . However, none of the reported work provides convincing evidence that, in vivo, there is any net flux of the carbon chain of GHB to GABA. In vivo, the SSA formed as a product of the oxidation of GHB by either cytosolic GHB dehydrogenase or the mitochondrial transhydrogenase would encounter not only GABA transaminase but also SSA dehydrogenase. The latter enzyme is an extremely active enzyme with a K m for SSA of 1.0 x 10 -5 M or less (40) and pulls the reaction catalyzed by GABA transaminase in the direction of SSA formation. One would expect that most of the SSA formed in vivo by the enzymatic action of GHB dehydrogenase or by the mitochondrial transhydrogenase would, like SSA formed by GABA transaminase, be rapidly oxidized to succinate.
SUMMARY
Two enzymes have been found which catalyze the initial step in the catabolism of GHB. The oxidation of GHB to SSA, catalyzed by both of these enzymes, is coupled to the reduction of an oxoacid. In the case of the mitochondrial transhydrogenase, the coupling is obligatory. Although coupling is not obligatory for the GHB dehydrogenase, the stimulation provided by the coupled reaction, and the nature of the kinetics of the uncoupled reaction, may not only allow the reaction to proceed, but may provide a means of regulating the rate of the reaction under in vivo conditions. Since the oxidation of GHB to SSA is the rate limiting step in the overall catabolic pathway (the rate of conversion of GHB to SSA proceeds at approximately one one thousandth of the rate at which SSA is oxidized to succinate by SSA dehydrogenase (30)), factors which regulate the rate of either or both of these enzymes will, in turn, influence tissue levels of endogenous GHB as well as the duration and magnitude of the physiological effect of a dose of GHB.
